Related Experiment Videos
Proteomics to diagnose human tumors and provide prognostic information
David K Ornstein1, Emmanuel F Petricoin
1Department of Urology, University of California, Irvine UCI Medical Center, Orange, California 92868, USA. dornstei@uci.edu
Oncology (Williston Park, N.Y.)
|May 12, 2004
Summary
Proteomics offers promising cancer biomarkers through advanced techniques like laser capture microdissection and mass spectrometry. These methods enable precise protein analysis for improved cancer diagnostics and prognostics.
Area of Science:
- Proteomics
- Biomarker Discovery
- Cancer Diagnostics
Background:
- Proteomics is crucial for identifying novel diagnostic and prognostic biomarkers in human cancer.
- Technological advancements allow detailed profiling of cellular protein composition.
Purpose of the Study:
- To review emerging proteomic technologies for cancer biomarker discovery.
- To highlight the transition of proteomics from discovery to clinical application.
Main Methods:
- Laser capture microdissection for pure cell populations.
- Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) for protein separation.
- Differential in-gel electrophoresis (DIGE) and isotope-coded affinity tagging (ICAT) for comparative proteomic analysis.
- Reverse-phase protein arrays and surface-enhanced laser-desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry for quantitative assessment and rapid analysis.
Main Results:
- Technological improvements enhance resolution, sensitivity, and reproducibility in proteomic surveys.
- Image analysis, robotics, DIGE, and ICAT facilitate comparison and isolation of differentially expressed proteins.
- SELDI-TOF mass spectrometry combined with AI algorithms generates accurate diagnostic information.
Conclusions:
- Proteomic technologies are evolving into valuable clinical tools for cancer detection and treatment.
- Mass spectrometry-based serum proteomics shows significant potential for clinical utility in oncology.